Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04298606 · ClinicalTrials.gov registry record · Early Phase 1
A Vaccine (CIMAvax-EGF) for the Prevention of Lung Cancer Development or Recurrence
A Early Phase 1 study, sponsored by Roswell Park Cancer Institute.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 20
- Enrollment target
NCT04298606 is a Early Phase 1 study that has completed, run by Roswell Park Cancer Institute. The registered enrollment target is 20 participants.
The verdict
NCT04298606, a Early Phase 1 study, has completed, sponsored by Roswell Park Cancer Institute.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 20 participants
- Enrollment target
Study Summary
This early phase I trial studies the side effects of a vaccine called CIMAvax-EGF and to see how well it works in preventing lung cancer from developing in patients at high risk for lung cancer or coming back (recurrence) in stage IB-IIIA non-small cell lung cancer survivors. In many cancers such as lung cancer, there is a protein receptor called EGFR (epidermal growth factor receptor) that is overexpressed within these cancers. Activation of EGFR has shown to lead to tumor growth and development. Previous studies have indicated that EGFR activation is present in the airways of cancer-free subjects as well. CIMAvax-EGF vaccine works by causing the body to make antibodies against EGF that is being produced that could be possibly driving the risk for developing cancer.
Interventions
- OTHER Quality-of-Life Assessment
- OTHER Questionnaire Administration
- BIOLOGICAL Recombinant Human EGF-rP64K/Montanide ISA 51 Vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2021-11-22 |
| Est. Completion | 2026-02-06 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04298606
The ClinicalTrials.gov registry entry for NCT04298606 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Roswell Park Cancer Institute, which has 365 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Quality-of-Life Assessment is the first listed.
NCT04298606 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04298606 about?
NCT04298606 is a clinical study titled "A Vaccine (CIMAvax-EGF) for the Prevention of Lung Cancer Development or Recurrence". This early phase I trial studies the side effects of a vaccine called CIMAvax-EGF and to see how well it works in preventing lung cancer from developing in patients at high risk for lung cancer or coming back (recurrence) in stage IB-IIIA non-small cell lung cancer survivors. In many cancers such as...
What is the current status of trial NCT04298606?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 20 participants. The study started on 2021-11-22. Estimated completion is 2026-02-06.
What interventions are being tested in trial NCT04298606?
The interventions under investigation include: Quality-of-Life Assessment (OTHER), Questionnaire Administration (OTHER), Recombinant Human EGF-rP64K/Montanide ISA 51 Vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT04298606?
This trial is sponsored by Roswell Park Cancer Institute, which has 365 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.